INS and type 1 diabetes mellitus: In particular, new algorithm-controlled insulin delivery systems based on real-time CGM, also named hybrid closed-loop systems (HCLs), have changed the clinical landscape, by providing new therapeutic targets, as well as an increase in the proportion of people with type 1 diabetes safely achieving those goals [4].